Thalidomide inhibits the replication of human immunodeficiency virus type 1 - Wikidata - awgldk - TriplyDB

Thalidomide inhibits the replication of human immunodeficiency virus type 1

Thalidomide inhibits the replication of human immunodeficiency virus type 1

http://www.wikidata.org/entity/Q28378516

about

Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro Hydroxyurea inhibits the transactivation of the HIV-long-terminal repeat (LTR) promoter Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus Thalidomide inhibits lipoarabinomannan-induced upregulation of human immunodeficiency virus expression Inhibition of tumor necrosis factor alpha alters resistance to Mycobacterium avium complex infection in mice.Autoimmune mechanisms of depletion of CD4 cells in HIV infection.Thalidomide: a remarkable comeback.Tat-independent replication of human immunodeficiency viruses.Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication by transcriptional activation at the long terminal repeat.Immunopathogenesis of human immunodeficiency virus: implications for immune-based therapies.Teratogenic effects of thalidomide: molecular mechanisms.Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update.Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients Dermatologic and nondermatologic uses of thalidomide.Human immunodeficiency virus endocrinopathy.Tumor necrosis factor-alpha mediates orthopedic implant osteolysis.Interleukin 1 induces HIV-1 expression in chronically infected U1 cells: blockade by interleukin 1 receptor antagonist and tumor necrosis factor binding protein type 1.Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid Guideline for the clinical use and dispensing of thalidomide Thalidomide--the way forward.Palladium-catalyzed one-step synthesis of isoindole-1,3-diones by carbonylative cyclization of o-halobenzoates and primary amines.Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor.Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production.Atherosclerosis: pathogenesis and increased occurrence in individuals with HIV and Mycobacterium tuberculosis infection Measurement of induced cytokines in AIDS clinical trials using whole blood: a preliminary report. ACTG Inducible Cytokines Focus Group. AIDS Clinical Trials Group.Enhanced responsiveness to nuclear factor kappa B contributes to the unique phenotype of simian immunodeficiency virus variant SIVsmmPBj14.Immune-based therapies for treatment of HIV infection.Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-alpha by mononuclear cells.Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis.Idiopathic giant oesophageal ulcer in an immunocompetent patient. The efficacy of thalidomide treatment.Thalidomide revisited: pharmacology and clinical applications.Inflammatory pseudotumor causing small bowel obstruction and mimicking lymphoma in a patient with AIDS: clinical improvement after initiation of thalidomide treatment.Investigation of the enantiomerization barriers of the phthalimidone derivatives EM12 and lenalidomide by dynamic electrokinetic chromatography.The return of thalidomide: are birth defects surveillance systems ready?CUL5 is required for thalidomide-dependent inhibition of cellular proliferation.[Thalidomide in Brazil: monitoring with shared responsibility?].Amino acid derivatives. Part 6. Synthesis, in vitro antiviral activity and molecular docking study of new N-α-amino acid derivatives conjugated spacer phthalimide backbone Involvement of nitric oxide on the pathogenesis of irinotecan-induced intestinal mucositis: role of cytokines on inducible nitric oxide synthase activation Treatment of AIDS-associated prurigo nodularis with thalidomide

P2860

Q24550678-BF96C075-211A-4A3B-A258-8B5A11E6A916 Q28343837-4165CE7D-EEAC-4C26-8E4A-987F25D5A2D1 Q28344235-C450CA63-541F-4017-B7BF-0BDA3C5FE9B2 Q28376504-6D3FE1B0-2964-4BEF-96C5-1AC94DC036F6 Q28378797-3BD76928-EFDA-4BCC-B30F-2259452DB504 Q33696833-AF40B820-D9A4-4FB1-B9CB-FDE64D86B52A Q34062232-182FFC36-81D9-4704-94C2-CEF81B66EDD4 Q34182143-F7F425EA-B135-4850-9EDC-64D40200486D Q34195783-274CA1C2-DD91-4160-AB1D-93678A9DF967 Q34218737-91DF5C6B-BF06-4AED-BF52-EE7BDAA306DF Q34255648-49E792EC-3D45-40A4-94E8-5FB8829CACA4 Q34660391-C254DF84-3AB2-4C12-8148-2624006A7691 Q35026302-2C275CE3-7A95-4030-A778-86FA3347537C Q35139592-A0315A7D-0BCB-4168-9EC1-057FDE72B7C9 Q35201057-4C9BC505-0116-4DB6-9132-C3ED4DE27868 Q35352448-E725EB9D-5F64-4345-8C91-0C18D3B96048 Q35754620-80EDD98A-16CF-4244-ACB0-582EBF48C355 Q36437556-15410C8F-3189-4F75-AB83-DB72B8A993CA Q36617691-A1EE89A4-2B97-4071-A984-E1701E18BAF6 Q36679796-EC5CBD0F-982B-4D63-AB5B-C7BD01BE0518 Q36679828-13B7A896-A976-4D86-AF04-843CF3F173AA Q37112591-06DCC1A6-F612-4A74-AE35-E96038ABE732 Q37372701-08F58F3B-52B5-4C5A-9221-D91916D88E64 Q37426004-031B486B-2693-4BB2-BB1E-50786BBC9A2C Q37957875-BFDC65AD-F1BA-4DE5-9FF3-663F91B54726 Q39505870-98D9A9A6-E614-437F-8460-1E59CAA6C7FC Q40042834-BD9030B3-E6DB-4F2C-9C50-0FDE76280067 Q40959127-08F402A0-093E-47DF-9CFF-C7EC5C658F80 Q41232618-92EC81CF-D2BF-44EC-91D8-E39A3872684E Q41874546-4C7DD207-4253-45BF-8986-255D5CCBFE90 Q43086866-8B234D0E-446D-44B1-9A5B-313911970E75 Q43596294-C98462EA-C887-4122-91ED-CA483107CD33 Q44872003-6E8CA4EA-5966-4736-8877-BDBD4CBD993F Q50994881-C7E4CA88-4C61-4B56-B58D-8719A8BE3D76 Q52191299-8A4A5F26-8477-46A5-9FBF-0E0D8120D1AC Q54215914-9DD17269-CEA5-4192-B012-7640378D5F5B Q55032965-185D9A3D-593D-4472-A6A8-325FA906D8D4 Q57269135-D74EF3D0-B4EC-4265-8CBD-E52A0F2900B4 Q57450697-63CE73B1-A8C1-4FF7-9E84-34D9F487A279 Q58000955-C19438AF-78F9-49D0-AE45-FDE11753AA67

P2860

Thalidomide inhibits the replication of human immunodeficiency virus type 1

http://www.wikidata.org/entity/Q28378516

description

1993 nî lūn-bûn

@nan

1993 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

1993 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

1993年の論文

@ja

1993年論文

@yue

1993年論文

@zh-hant

1993年論文

@zh-hk

1993年論文

@zh-mo

1993年論文

@zh-tw

1993年论文

@wuu

name

Thalidomide inhibits the replication of human immunodeficiency virus type 1

@ast

Thalidomide inhibits the replication of human immunodeficiency virus type 1

@en

Thalidomide inhibits the replication of human immunodeficiency virus type 1

@nl

type

label

Thalidomide inhibits the replication of human immunodeficiency virus type 1

@ast

Thalidomide inhibits the replication of human immunodeficiency virus type 1

@en

Thalidomide inhibits the replication of human immunodeficiency virus type 1

@nl

prefLabel

Thalidomide inhibits the replication of human immunodeficiency virus type 1

@ast

Thalidomide inhibits the replication of human immunodeficiency virus type 1

@en

Thalidomide inhibits the replication of human immunodeficiency virus type 1

@nl

P1433

Q28378516-F6555DFA-B697-4F3B-8C9D-DBC9B3B2FE64

P1476

Q28378516-12CF9F93-E6C8-4A30-9611-0FC649D4AC91

P2093

Q28378516-4626A4B5-6C5F-4271-815C-D4EBA8CB2F6C

Q28378516-654F7057-F3F6-4BC3-9C0E-846B10C69BFA

Q28378516-68B37F39-0A48-4809-A3E9-D0321F43BC6E

Q28378516-75ACAF60-B66D-4DD4-A5C1-0846B6631491

Q28378516-BF2F7137-F6C6-4922-A351-92E318C38BC5

P2860

Q28378516-10EFB140-83CC-4746-94C8-B095FD5AA340

Q28378516-2FC4AE68-0E11-4B70-93C3-3B5F63C170E6

Q28378516-35F69348-6C60-4A3F-B95F-0D1674C28E9B

Q28378516-3E493EFE-D1EA-4355-903D-E906070C2DDA

Q28378516-4B57C185-EE36-4441-A10D-EBF087C8E02B

Q28378516-4E6EADFA-09CE-4BB4-B7E8-5AF65E841AD9

Q28378516-85255893-22E5-4E3B-8ABF-E3AEACB3F644

Q28378516-8CF19FF2-9477-4549-895E-54BB9663B888

Q28378516-9BE3AD77-491A-485A-ACB3-7314AD6922E0

Q28378516-B0D0E317-1A06-450F-A8A3-76129E892D0B

P304

Q28378516-6B8D855B-39E3-454D-8EE2-D8552DE80A57

P31

Q28378516-831F91BA-5824-4FDD-AB1C-B90495807A3E

P356

Q28378516-50B70C0D-6337-4231-BB5B-89DC458C6D19

P407

Q28378516-3329AC3F-1836-4B70-A7B9-45B89D21AAE9

P433

Q28378516-1D4BBE4E-4789-4D1A-AB86-B31236EBD001

P478

Q28378516-4A167AD0-3E92-4E7D-BA06-3531CBE8DA53

P577

Q28378516-E80D6F9C-142A-4C72-9955-A8DB7904385A

P5875

Q28378516-5F398BFC-F8CF-4A89-8EC1-AFC388ED13DF

P698

Q28378516-E3195001-3A31-405F-86A1-2AE81DDE3A6F

P921

Q28378516-1A6D5D8F-C6B4-48CA-8769-DEFA01FB2F2A

P932

Q28378516-7B16F4BC-B8D1-4BFF-9CFD-494DEA337CEC

P356

PNAS.90.13.5974

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Thalidomide inhibits the replication of human immunodeficiency virus type 1

@en

P2093

A L Moreira

http://www.w3.org/2001/XMLSchema#string

G Kaplan

http://www.w3.org/2001/XMLSchema#string

R N Limson-Pobre

http://www.w3.org/2001/XMLSchema#string

S Makonkawkeyoon

http://www.w3.org/2001/XMLSchema#string

V Schauf

http://www.w3.org/2001/XMLSchema#string

P2860

Pentoxifylline (Trental) decreases the replication of the human immunodeficiency virus type 1 in human peripheral blood mononuclear cells and in cultured T cells

Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone.

Shock and tissue injury induced by recombinant human cachectin.

Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat.

The effect of cytokines and pharmacologic agents on chronic HIV infection.

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

Human tumor necrosis factor alpha gene regulation in phorbol ester stimulated T and B cell lines

Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients

NIH conference. Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection.

Immune mechanisms in bacterial and parasitic diseases: protective immunity versus pathology.

P304

5974-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.90.13.5974

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

90

http://www.w3.org/2001/XMLSchema#string

P577

1993-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14870769

http://www.w3.org/2001/XMLSchema#string

P698

8327469

http://www.w3.org/2001/XMLSchema#string

P921

P932

46849

http://www.w3.org/2001/XMLSchema#string